An interventional study of gastric bypass and Sleeve gastrectomy in Severe Obesity, sponsored by Göteborg University. Active, not recruiting at 21 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-02-09.
Sponsored by Göteborg University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Obesity, Morbid with a site in Sweden — 3 open to participants now, 5 under way, none of them phase 3. Obesity, Morbid · Sweden.
Among the 16 studies in Obesity, Morbid with a site in Sweden, this one is one of 2 that started in 2015, is one of 8 with no phase, and was the 10th registered.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
Browse Obesity, Morbid studies →3 of the 16 studies in Obesity, Morbid with a site in Sweden are open now. Recruiting first, the newest first:
Umeå University · Sites in Sweden
Ages 18+
Göteborg University · Sites in Sweden
Ages 18+
Uppsala University · Sites in Sweden
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2015.
This study's enrollment of 1,752 is above the median of 62 across 601 interventional studies indexed under Obesity, Morbid.
Median enrollment 140 across the 9 interventional studies, 1,400 across the 7 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 16 have an industry lead sponsor. The 9 most frequent:
Göteborg University is the lead sponsor of 272 studies on the registry; 47 are open to participants now.
Göteborg University has 4 studies filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
2 of the studies in Obesity, Morbid with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02767505Göteborg UniversityBypass Equipoise Sleeve Trial (BEST) | 2026-12 |
| NCT03152617Göteborg UniversityBASUN - Risks for Malnutrition, Metabolic Bone Disease and Impaired Oral Health After Obesity Treatment | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Obesity, Morbid with a site in Sweden, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is nationwide registry-based randomised clinical multicenter trial in which patients will be randomised to gastric bypass (RYGB) or sleeve gastrectomy (SG). The co-primary endpoint are weight control over 5 years and the amount of severe adverse events. Additionally the investigators have predefined a number of secondary endpoints, and the trial has a sufficient number of patients to allow comparisons across subgroups.
Follow-up of the patients will use the routines respectively for regular follow-up on the Scandinavian Obesity Surgery Registry (SOReg) after 6v, 1 year, 2 years, and after 5 years.
In order to evaluate if SG has advantages compared to the previous standard, the investigators want to examine whether SG operations are equivalent (non-inferiority) for weight loss and weight stability five years after surgery in comparison to RYGB, and if SG is associated with fewer long-term complications (superiority). The primary outcome measure emanates from assessment of long term weight management and the frequency of serious complications.
The unforeseen global Covid-19 pandemic resulted in that almost all elective benign surgery in Scandinavia was cancelled from March 2020. Thus, the pandemic had severe consequences on the recruitment to the BEST trial during 2020-2021.
During autumn of 2021 the BEST steering committee decided to perform an additional analysis of the power for primary endpoints.
Additional information (Courcoulas et al, JAMA Surg 2020 March; Howard et al, JAMA Surg 2021 Dec) revealed that the risk of any of the predefined substantial adverse events after bariatric surgery is higher than previously anticipated in the revised power calculation, i.e. >25% instead of 13%. These figures were confirmed in an analysis of real-world data from the bariatric national quality register SOReg in Sweden which registered all patients undergoing sleeve or bypass in Sweden since 2007.
An independent statistician performed the analysis based on information above, but also on 2-year data in BEST. In conclusion, it was stated:
Two post hoc power analyses were conducted based on the data from February 2022:
Taking information above into account and in the interest of not prolonging inclusion period unnecessarily the trial steering committee took a decision to stop inclusion in BEST during spring 2022 (final date 31st of March). At termination of inclusion the number of participants that had been included and operated in BEST were 1752. The trial Data Safety and Monitoring Committee reviewed and supported the decision before termination of recruitment to the BEST trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Laparoscopic sleeve gastrectomy
Other: Sleeve gastrectomy
Laparoscopic Roux-en-Y gastric bypass
Other: gastric bypass
Type of surgery: gastric bypass
Typ of surgery: sleeve gastrectomy
Weight loss
Non-inferiority for SG is defined as \< 5% weight difference
Time frame: 5 years
Serious adverse events
Superiority for SG is having 35% less serious (substantial) adverse events compared to RYGB
Time frame: 5 years
Adverse events
General description of patterns of all adverse events
Time frame: 1, 2, 5 and 10 years
Weight loss
Between baseline and 1 and 2 years
Time frame: Baseline, 1, 2, 5 and 10 years
Number of patients with arterial cardiovascular events
Composite of myocardial infarction+ stroke+ other occlusive arterial condition
Time frame: Baseline, 1, 2, 5 and 10 years
Number of patients with venous event
Composite of Deep vein thrombosis+ Pulmonary emboli+ other venous event
Time frame: Baseline, 1, 2, 5 and 10 years
Number of patients with diabetes requiring drug treatment
Development of diabetes measured as numbers of patients having a diabetes diagnosis and oral medication and injection therapy
Time frame: Baseline, 1, 2, 5 and 10 years
Number of patients with a psychiatric morbidity
Number of patients with a psychiatric morbidity
Time frame: Baseline, 1, 2, 5 and 10 years
Number of patients with hypertension treatment
Number of patients with hypertension treatment (any type of Medical treatment)
Time frame: Baseline, 1, 2, 5 and 10 years
Number of patients diagnosed with a malignancy
Number of patients diagnosed with a malignancy
Time frame: Baseline, 1, 2, 5 and 10 years
Number of patients with dyslipidemia treatment
Number of patients with diagnosis of dyslipidemia and on oral lipid lowering treatment
Time frame: Baseline, 1, 2, 5 and 10 years
Weight in men and women
Analyses of the primary outcome weight in men and women
Time frame: Baseline, 1, 2, 5 and 10 years
serious adverse events in men and women
Analyses of the primary outcome serious adverse events in men and women
Time frame: Baseline, 1, 2, 5 and 10 years
Weight in patients with BMI >43 vs <43 kg/m2.
Analyses of the primary outcome weight in patients with BMI \>43 vs \<43 kg/m2.
Time frame: Baseline, 1, 2, 5 and 10 years
Serious adverse events in patients with BMI >43 vs <43 kg/m2
Analyses of the primary outcome serious adverse events in patients with BMI \>43 vs \<43 kg/m2.
Time frame: Baseline, 1, 2, 5 and 10 years
Weight in patients aged 18-25 y, 25-50 y, or >50 y
Analyses of the primary outcome weight in patients aged 18-25 y, 25-50 y, or \>50 y
Time frame: Baseline, 1, 2, 5 and 10 years
Serious adverse events in patients aged 18-25 y, 25-50 y, or >50 y
Analyses of the primary outcome serious adverse events in patients aged 18-25 y, 25-50 y, or \>50 y
Time frame: Baseline, 1, 2, 5 and 10 years
Mineral nutritional status
Serum concentrations of iron depots, zinc, magnesium, selenium and copper
Time frame: Baseline, 1, 2, 5 and 10 years
Vitamin nutritional status
Serum concentrations of vitamins (Vitamin B12, Vitamin D, Vitamin A, thiamin)
Time frame: Baseline, 1, 2, 5 and 10 years
Serum concentrations of albumin
Serum concentrations of Albumin
Time frame: Baseline, 1, 2, 5 and 10 years
Changes in quality of Life assessed with EQ-5D
Assessed with EQ-5D
Time frame: Baseline, 1, 2, 5 and 10 years
Changes in quality of Life assessed with Obesity Problems (OP)
Assessed with Obesity Problems (OP)
Time frame: Baseline, 1, 2, 5 and 10 years
Changes in quality of Life assessed with Short Form-36
Assessed with SF-36
Time frame: Baseline, 1, 2, 5 and 10 years
Alcohol consumption
Assessed by AUDIT
Time frame: 1, 2, 5 and 10 years
Gastro-esophageal reflux disease
Gastro-esophageal reflux disease is defined as present/ not present in at least one of following modalities: Questionnaire DeMeester score, 24h pH manometry and/or gastroscopy
Time frame: 1, 2, 5 and 10 years
Fracture incidence
From clinical data and national registry
Time frame: 2, 5 and 10 years
Bone density and body composition
Dual energy X-ray Absorptiometry (DEXA) in at least a subgroup of 500+500
Time frame: 10 years
Mortality and cause of death
National Cause of Death registry
Time frame: 5, 10, 20 and 30 years
Health care consumption, In hospital registry
Data from In hospital registry (Days in hospital)
Time frame: 5, 10, 20 and 30 years
Health care consumption,
Data from Outpatient registry ( number of visits)
Time frame: 5, 10, 20 and 30 years
Health care consumption
National drug registry (type of drug)
Time frame: 5, 10, 20 and 30 years
Development of co-morbidities from national registry data
National stroke registry, National Cardiac registry, National Diabetes Registry, Cancer registry
Time frame: 5, 10, 20, 30 years
Formal cost effective analysis
Cost per quality-adjusted life-year and life-year)
Time frame: 5, 10 and 20 years
Dietary intake
Questionnaire regarding food intake (E14x)
Time frame: 1 and 10 years
Eating patterns
Three Factor Eating Questionnaire (TFEQ)
Time frame: 1 and 10 years
Gastro-intestinal side effects
Questionnaire: Gastro-intestinal Symptom Rating Score (GSRS)
Time frame: 1 and 10 years
Dumping symptoms
Questionnaire: Dumping Symptom Rating Score (DSRS)
Time frame: 1 and 10 years
Adverse events
Clinical data combined with national registry data
Time frame: 30 days postop, 1, 2, 5 and 10 years
Peri-operative outcome, Complications
Complications; Surgical (minor/major) and medical
Time frame: Up to 30 days postop
Peri-operative outcome, surgical time
surgical time (min)
Time frame: Up to 30 days postop
Peri-operative outcome, sick leave
sick leave (days)
Time frame: Up to 30 days postop
Peri-operative outcome, length of stay
length of stay (days)
Time frame: Up to 30 days postop
Plan to share: No
The record gives a start of Sep 2015, a primary completion of Dec 2026 and a completion of Dec 2031. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.